Abstract
Early and accurate detection of prostate cancer (PCa) together with effective treatment can save lives. Despite the recent advances in its treatment, the mortality trends due to PCa, in the USA, continue to be alarming with annual increase of 3%. In this brief communication, we propose a novel approach to treat PCa, its metastasis and recurrence. This is guided by a large quantity of preliminary data driven by targeting an endogenous genetic product, VPAC, expressed in high density on the cell surface at the onset of genetic mutation that ignites the cancerous transformation.
A large body of preclinical and clinical data generated in our laboratory used a positron-emitting radionuclide Copper-64 (Cu-64), conjugated to a small biomolecule, TP 3805 that has a high in vivo stability and high affinity (Kd 3.1 × 10−9 M) for VPAC. The data depict high uptake of Cu-64-TP3805 in primary and metastatic lesions and malignant lymph nodes with minimal uptake in normal tissues except the liver, prompted by the hepatobiliary excretion.
Reflecting on the present and planning for the future, our quest is to systematically investigate the use of the beta-emitting sister radionuclide Cu-67 to target VPAC receptors for theranostic applications of primary and metastatic PCa.
You have full access to this open access chapter, Download chapter PDF
Similar content being viewed by others
Keywords
32.1 Introduction
Cancer is complex yet commonplace, and the most terrifying disease of mankind. Among men in the USA, prostate cancer (PCa) is particularly lethal, second only to cancers of the lung and bronchus combined [1]. In 2020, more than 30,000 men will succumb to PCa, and more than 240,000 new PCa cases will be identified in the USA alone [1]. PCa affects one in every 6 men who are 60 years or older and affects African-Americans at a rate 2.4 times greater than European-Americans [1].
To treat these patients effectively, clinicians have a large array of options. However, even the novel agents such as abiraterone and enzalutamide offer only a limited survival benefit to the patients. For patients with skeletal metastases, FDA-approved Radium-223 chloride, (Xofigo) enhances the survival for up to 3.6 months. Furthermore Ra-223 chloride targets only osteoblastic lesions and does not provide effective treatment to visceral or nodal metastatic lesions. A continued search for more effective treatment has recently led to the development of a theranostic agent Lutetium-177-PSMA-617 (Lu-177-PSMA-617), although not yet approved by FDA for use in the USA, is being commonly used in many continents such as Europe, Asia, Australia and South Africa. At the time of this writing, the agent is in clinical trials in the USA. With three or more cycles of Lu-177-PSMA-617 treatments of approximately 7.4 GBq (200 mCi) each, progression-free survival of up to 13.6 months has been reported [2]. The best success of the Lu-177-PSMA-617 treatment consists of >50% PSA decline in 45% of the patients, partial regression in 56%, stable disease in 7% and progressive disease in 3.6% of the patients [2,3,4]. Progression-free survival for 3.6 months to 13.7 months has also been reported [2,3,4].
Although the results are encouraging, several weaknesses of Lu-177-PSMA-617 treatment have surfaced. First, PSMA is expressed only on 80% to 85% of PCa which requires patient to be screened, for PSMA expression using Ga-68-PSMA-11 PET scan. Second, extensive uptake of Lu-177-PSMA-617 in salivary glands leaves most patients with mild-to-severe xerostomia to minimize which some investigators have chosen to block the uptake using botulinum toxin (another pre-Lu-177-PSMA-617 treatment procedure). Third, considerable myelocytic toxicity and fatigue have been also reported in patients receiving Lu-177-PSMA-617. Fourth, Lu-177-PSMA-617 has approximately 75% renal excretion in 24 h, exerting radiation risk to renal medulla and bladder wall. Blocking renal uptake with certain amino acids prior to Lu-177-PSMA-617 treatment, a third pretreatment procedure, has been also considered. Fifth, Lu-177 contains approximately 0.1% Lu-177 m as an impurity. Lu-177 m has a half-life of 110 days. The urinary excretion of up to 75% of injected Lu-177 m within 24 h together with the longer lived Lu-177 m creates a waste disposal problem particularly for those patients who are incontinent and wear diapers.
These issues, in addition to the pretreatment procedures, not only add to the treatment cost but are also undesirable to the patients already stressed emotionally and weakened physically. In addition, the PSMA treatment eliminates 15 to 20% of the needy PCa patients who do not express PSMA. Improved agents with similar or better therapeutic effectiveness but without the persistent weaknesses are desirable.
32.2 Our Approach
Our proposed approach to treat PCa, its metastases and recurrence is driven by targeting an endogenous genetic product overexpressed when cells suffer genetic mutations that ignite cancerous transformation. VPAC mediates VIP (vasoactive intestinal peptide) and PACAP (pituitary adenylate cyclase activating peptide) growth hormone function in all types of PCa irrespective of the PCa heterogeneity [5,6,7,8,9].
These characteristic fingerprints, the VPAC cell surface receptors, express themselves at the onset of the malignancy, and may be prior to the elevation of PSA, and well before the cell morphology is altered this forms the basis of histologic diagnosis [5]. However, the expression on malignant cell surface has not yet been investigated for treating PCa and its metastases. Over the past few years, we have developed a small radioactive molecule (Cu-64-TP3805) that has high-affinity (Kd 3.1 × 10−9 M) VPAC receptors expressed in high density on all PCa cells. Our PET imaging studies in humans have shown that Cu-64-TP3805 detects primary PCa, bone metastatic lesions, and malignant lymph nodes with >95% sensitivity [10,11,12,13,14,15,16,17,18,19]. Furthermore, the agent has no urinary excretion, has no salivary gland uptake, no bone marrow uptake, and only a small uptake in the renal cortex, not sensitive to radiation damage.
Copper-64 has other radionuclide, a beta-emitting Copper-67, (t½ 2.6 day, γ-185 KeV (40%) and βmax- 580 KeV) which can be easily used to synthesize Cu-67-TP3805 using a well-established procedure in our laboratory and can be used for theranostic applications in PCa patients. Since (1) the tissue range (0.6 mm) and the linear energy transfer for Cu-67 is the same as Lu-177,and since Cu-67-TP3805, will have (2) the same tissue distribution as that of Cu-64-TP-3805 with high uptake both in primary PCa and its metastatic lesions, (3) no urinary excretion, (4) no salivary gland uptake, and (5) since VPAC is expressed in high density on all PCa types, the Cu-67-TP3805 treatment will be readily applicable to all PCa patients without having to perform patient suitability examination or having to deliver any of the antitoxicity, preventive procedures. These virtues of Cu-67-TP3805 for theranostic applications are listed in Table 32.1.
32.3 VPAC Receptor and Its Expression on PCa
VPAC, a genomic biomarker, belongs to the superfamily of G protein-coupled surface receptors which are expressed in high density (104–105/cell) on all PCa types cells at the onset of oncogenesis [20,21,22,23,24,25]. On stroma, normal cells and benign masses VPAC is minimally present (5–10/cell). Since VPAC receptors are expressed on all PCa, for theranostic use of Cu-67-TP3805, patient-qualifying screening studies, like those required with Lu-177-PSMA-617 treatment, will not be necessary.
Reubi and colleagues [6,7,8,9] examined more than 600 tumors and their metastases using immunohistochemistry and conclusively reported that VPAC and VPAC2 receptors are overexpressed on a variety of frequently occurring human tumors including those of the breast and prostate. On 100% of the human prostate tumors examined (n = 35), VPAC receptors were predominantly overexpressed on PCa tissues and VPAC2 on stroma, to a lesser extent. Although VPAC receptors exist on normal cells, their expression is lower than on malignant cells on which the receptor density is high.
A 28 amino acid peptide VIP has high affinity for VIP receptors and the 27 amino acid peptide PACAP has high affinity for VIP and PACAP1 combined. VPAC receptors are overexpressed on all PCa including metastatic lesions (Figs. 32.1, 32.2, 32.3 and 32.4). High expression of VPAC receptors (>104/cell) has been observed by others. Both VIP28 and PACAP27 have high affinity for VPAC (VPAC and VPAC2 receptors) [6,7,8,9].
Therefore, we had hypothesized that radiolabeled VIP and PACAP1 or their analogues will provide us with excellent biomolecules for accurate and sensitive detection of human PCa. The probe can also detect metastases, and be used to determine therapeutic effectiveness.
32.4 VIP, PACAP, and Their Analogues
VIP is a 28-amino acid peptide initially isolated from porcine intestine [26]. VIP, whose structure is common in humans, pigs and rats, is a hydrophobic, basic peptide that contains three lysine (position 13, 18, 19) and two arginine (position 12, 14) residues. From the essential histidine residue at the N-terminus to the amidated C terminus, all 28 amino acids of VIP are required for high-affinity binding and biological activity [27].
VIP gene receptors (VIP1 and VIP2) have been detected on the cell membrane of normal intestinal [28] and bronchial epithelial cells [21,22,23] and are overexpressed on various cancer cells, including colonic adenocarcinoma [23, 29], pancreatic carcinoma [30], and cancers of the prostate [6,7,8,9]. VIP (Tyr10 and Tyr22) labeled with I-123 successfully imaged a number of human tumors [31]. Following PACAP homology, these gene receptors are recently named VPAC (for VIP1 and PACAP2 combined) and VPAC2 (for VIP2 and PACAP3 combined). PACAP, a 38-amino acid peptide, isolated from bovine hypothalamus, was named PACAP because it stimulated the accumulation of intracellular and extracellular cAMP in monolayer cultures of rat anterior pituitary cells [20, 32]. PACAP, a neurotransmitter and member of the VIP family, is ten times more potent than VIP in stimulating adenylate cyclase in pituitary cells [32]. PACAP has three gene receptors, PACAP1, 2, and 3. Gottschall et al. [33] isolated 27-amino acid PACAP (PACAP27) from bovine hypothalamus and concluded that PACAP38 and PACAP27 were equally active and derived from a single 176-amino acid precursor. PACAP27, like VIP, has an amidated C-terminus and histidine at the N-terminus. Nineteen of the 27 amino acids of PACAP27 are homologous. The fact that PACAP27 recognizes and has high affinity (Kd = 1.5 nM) for both VIP and PACAP (VPAC) receptors that are overexpressed on PCa cells suggests that PACAP or its bioactive analogue may also be a suitable agent to image PCa [8, 10,11,12,13,14,15,16,17].
32.5 Synthesis of N2(S-Benzyl)2 Containing VIP and PACAP
We synthesized one analogue of VIP28 (TP3939) and one of PACAP27 (TP3805) that are more potent and biologically stable than VIP28. Vasoactive intestinal peptide (VIP) bound to a C-terminal diaminodithiol (N2S2) chelator was synthesized on a Wang resin using ABI 341A peptide synthesizer (Applied Biosystems, Inc.) [10, 18]. The analogues were prepared, purified, and characterized by American Peptide Company (Sunnyvale, CA) and named after their molecular weights as TP3805 and TP3939. Although peptides have been conjugated with chelating agents such as DOTA (1, 4, 7, 10-tetraazadocdecane -N, N″, N′, N, −tetra acetic acid), it requires a prepared and pre-purified peptide to which DOTA is to be conjugated. The conjugated product then needs further purification and characterization. Preparation of our analogues is a one-step process that provides efficiency, saves time, and provides a N2S2 type of chelating moiety for strong chelation with Cu-64.
Our data show that these Cu-64 probes are highly stable in vivo [11, 12]. Furthermore, the high VIP affinity for receptors on malignant cells and subsequent internalization minimizes its proteolysis and allows cell detection, as we have demonstrated in both mice and humans [10,11,12,13,14,15,16,17,18,19, 34]. These analogues have the high IC50 values (4.4 nM and 5.3 nM, respectively) among the many that have been synthesized and evaluated [20, 32].
The rationale for choosing TP3939 analogues was as follows. VIP28 is comprised of three aromatic moieties at Phe6, Tyr10, and Tyr22, a negatively charged site at Asp3 and a lone pair structure at His1. Although all five sites are required for complete binding to receptors with high affinity, substitutions at position 22 of 3-OCH3–4-OH-Phe and Lys12, Nle17, Val26, Thr28-VIP produced the best results, increasing potency by four times (IC50 = 4.4 nM vs. 15 nM) over VIP28. Higher affinity may enhance tumor uptake and improve image quality. Again, our recent preliminary data in humans, obtained using Tc-99 m-TP3654, a VIP analogue are consistent with this hypothesis [34].
32.6 Cu-64-TP3805 and Its Tissue Distribution in Humans
Cu-64-TP3805, designed and extensively validated in our receptors laboratory, has a high affinity (3.1 × 10−9 M) for VPAC receptors [10, 18, 19]. The agent is highly stable in vivo, has no urinary excretion, has no salivary gland uptake, and has renal uptake only in the cortex, resistant to radiation damage (Fig. l). The hypothesis therefore is that by targeting VPAC receptors will eliminate (a) patient treatment qualifying PET imaging, (b) subsequent xerostomia without botulinum toxin pretreatment, and (c) reduce renal toxicity preventing renal pretreatment.
32.7 Ability of VPAC Target to Image Primary PCa, and Its Metastases in Bone and Lymph Nodes
Following targeting VPAC receptors, and validating our hypothesis in TRAMP (Transgenic Adenocarcinoma of the Mouse Prostate) mice, we have studied 45 patients with primary PCa and metastatic lesions by PET imaging with Cu-64-TP3805 [18]. As confirmed by postsurgical histology, all primary and metastatic lesions were imaged with >95% sensitivity (Figs. 32.2, 32.3 and 32.4). These data support the notion that VPAC is a highly suitable target for theranostic applications of Cu-67-TP3805 for treating PCa and its metastatic lesions.
32.8 Suitability of Cu-67 for Theranostic Application
Copper-67 is a commercially available, 2.6 day half-lived radionuclide that has radiation characteristics similar to that of Lu-177 (Table 32.2), including its β tissue range of 0.6 mm and linear energy transfer (LET). Since Cu-67 has the same chemical properties as that of Cu-64, we can prepare Cu-67-TP3805 using the same well-established procedure in our laboratory. Therefore, Copper-67, available commercially without longer lived radionuclide contamination, can be easily prepared as Cu-67-TP3805 and be effectively used to target VPAC receptors. The attractive radiation characteristics of Cu-67 have already drawn considerable attention leading to clinical trials treating neuroblastoma using SARTATE™ composed of Cu-67-labeled peptide, MeCOSar-Tyr3-octreatate [35] (Table 32.2).
Reflecting on the present, planning for the future and prompted by the highly encouraging results in our laboratory, our quest is to systematically investigate targeting VPAC receptors using beta-emitting Cu-67-TP3805 for theranostic applications of primary and metastatic PCa. In addition to the anticipated high benefit-to-risk ratio of Cu-67-TP3805 as a theranostic, VPAC receptors are expressed on many other oncologic diseases, such as the cancers of the breast, bladder, lung, ovary, and brain [6,7,8,9, 13, 17, 36, 37]. It is therefore, reasonable to postulate that Cu-67-TP3805 may serve as a useful theranostic agent to treat many other cancers as well.
References
Cancer Facts & Figures 2019. American Cancer Society. 2019. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf.
Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, Schottelius M, Mueller D, Klette I, Wester H-J. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57(7):1006–13. https://doi.org/10.2967/jnumed.115.168443.
McBean R, O’Kane B, Parsons R, Wong D. Lu177-PSMA therapy for men with advanced prostate cancer: initial 18 months experience at a single Australian tertiary institution. J Med Imaging Radiat Oncol. 2019;63:538. https://doi.org/10.1111/1754-9485.12891.
Turner JH. Recent advances in theranostics and challenges for the future. Br J Radiol. 2018;91(1091):20170893. https://doi.org/10.1259/bjr.20170893; Epub 2018/03/23. PubMed PMID: 29565650; PMCID: PMC6475948.
Lelievre VPN, Wasche JA. In: Vaudry HAA, editor. The biological significance of PACAP and PACAP receptors in human tumors: from cell lines to cancers. Springer Publishing Co.; 2003.
Reubi JC. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J Nucl Med. 1995;36(10):1846–53.
Reubi JC, Laderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res. 2000;60(11):3105–12.
Reubi JC. In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Ann N Y Acad Sci. 2000;921:1–25.
Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med. 1995;36(10):1825–35.
Thakur ML, Aruva MR, Gariepy J, Acton P, Rattan S, Prasad S, Wickstrom E, Alavi A. PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog. J Nucl Med. 2004;45:1381–9.
Zhang KAM, Shanthly N, Cardi CA, Rattan S, Patel C, Kim C, McCue PA, Wickstrom E, Thakur ML. PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer. J Nucl Med. 2008;49(1):112–21. https://doi.org/10.2967/jnumed.107.043703; PMCID: PMC5850935.
Zhang K, Aruva MR, Shanthly N, Cardi CA, Patel CA, Rattan S, Cesarone G, Wickstrom E, Thakur ML. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: in vitro/in vivo evaluation. Regul Pept. 2007;144(1–3):91–100. https://doi.org/10.1016/j.regpep.2007.06.008; PubMed PMID: 17727979; PMCID: PMC2587158.
Leylon FPJJS, et al. VIP 1 receptors are present in breast cancer biopsy specimens. Am Assoc Cancer Res. 1998;38:117.
Pallela VR, Thakur ML, Chakder S, Rattan S. 99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies. J Nucl Med. 1999;40(2):352–60; Epub 1999/02/20.
Kolan HRPV, Thakur ML. Technetium-99m labeled vasoactive intestinal peptide, (VIP): preparation and preliminary evaluation. J Label Compd Radiopharm. 1997;40(11):721–811. https://doi.org/10.1002/jlcr.2580401101.
Rao PS, Thakur ML, Pallela V, Patti R, Reddy K, Li H, Sharma S, Pham HL, Diggles L, Minami C, Marcus CS. 99mTc labeled VIP analog: evaluation for imaging colorectal cancer. Nucl Med Biol. 2001;28(4):445–50.
Thakur ML. Genomic biomarkers for molecular imaging: predicting the future. Semin Nucl Med. 2009;39(4):236–46. https://doi.org/10.1053/j.semnuclmed.2009.03.006; PubMed PMID: 19497401; PMCID: PMC2731478.
Tripathi SKTE, Gomella L, Kim S, McCue P, Intenzo C, Birbe R, Gandhe A, Kumar P, Thakur M. VPAC1 targeted (64)cu-TP3805 positron emission tomography imaging of prostate cancer: preliminary evaluation in man. Urology. 2016;88:111–8. https://doi.org/10.1016/j.urology.2015.10.012; PMCID: PMC4788593.
Trabulsi EJ, Tripathi SK, Gomella L, Solomides C, Wickstrom E, Thakur ML. Development of a voided urine assay for detecting prostate cancer non-invasively: a pilot study. BJU Int. 2017;119(6):885–95. https://doi.org/10.1111/bju.13775; Epub 2017/01/12. PubMed PMID: 28075510; PMCID: PMC5444967.
Bolin DR, Cottrell J, Garippa R, Michalewsky J, Rinaldi N, Simko B, O’Donnell M. Structure-activity studies on the vasoactive intestinal peptide pharmacophore. 1. Analogs of tyrosine. Int J Pept Protein Res. 1995;46(3–4):279–89. https://doi.org/10.1111/j.1399-3011.1995.tb00599.x; Epub 1995/09/01.
Paul S, Said SI. Characterization of receptors for vasoactive intestinal peptide solubilized from the lung. J Biol Chem. 1987;262(1):158–62; Epub 1987/01/05.
Moody TW. Peptides and growth factors in non-small cell lung cancer. Peptides. 1996;17(3):545–55. https://doi.org/10.1016/0196-9781(95)02148-5; Epub 1996/01/01.
Couvineau A, Laburthe M. The human vasoactive intestinal peptide receptor: molecular identification by covalent cross-linking in colonic epithelium. J Clin Endocrinol Metab. 1985;61(1):50–5. https://doi.org/10.1210/jcem-61-1-50; Epub 1985/07/01.
Sreedharan SP, Robichon A, Peterson KE, Goetzl EJ. Cloning and expression of the human vasoactive intestinal peptide receptor. Proc Natl Acad Sci U S A. 1991;88(11):4986–90. https://doi.org/10.1073/pnas.88.11.4986; Epub 1991/06/01. PubMed PMID: 1675791; PMCID: PMC51792.
Zia H, Leyton J, Loecho T, Moody TW. PACAP receptors are present on breast cancer cell lines. Am Assoc Cancer Res. 1997;38:117.
Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science. 1970;169(3951):1217–8.
Chakder S, Rattan S. The entire vasoactive intestinal polypeptide molecule is required for the activation of the vasoactive intestinal polypeptide receptor: functional and binding studies on opossum internal anal sphincter smooth muscle. J Pharmacol Exp Ther. 1993;266(1):392–9.
Blum AM, Mathew R, Cook GA, Metwali A, Felman R, Weinstock JV. Murine mucosal T cells have VIP receptors functionally distinct from those on intestinal epithelial cells. J Neuroimmunol. 1992;39(1–2):101–8. https://doi.org/10.1016/0165-5728(92)90179-o; Epub 1992/07/01.
el Battari A, Martin JM, Luis J, Pouzol O, Secchi J, Marvaldi J, Pichon J. Solubilization of the active vasoactive intestinal peptide receptor from human colonic adenocarcinoma cells. J Biol Chem. 1988;263(33):17685–9; Epub 1988/11/25.
Le Meuth V, Farjaudon N, Bawab W, Chastre E, Rosselin G, Guilloteau P, Gespach C. Characterization of binding sites for VIP-related peptides and activation of adenylate cyclase in develo** pancreas. Am J Phys. 1991;260(2 Pt 1):G265–74. https://doi.org/10.1152/ajpgi.1991.260.2.G265; Epub 1991/02/01.
Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, Li S, Banyai M, Pidlich J, Niederle B, Scheithauer W, Valent P. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med. 1994;331(17):1116–21. https://doi.org/10.1056/NEJM199410273311703.
Bolin DR, Cottrell J, Garippa R, Rinaldi N, Senda R, Simko B, O’Donnell M. Comparison of cyclic and linear analogs of vasoactive intestinal peptide. Drug Des Discov. 1996;13(3–4):107–14; Epub 1996/04/01.
Gottschall PE, Tatsuno I, Miyata A, Arimura A. Characterization and distribution of binding sites for the hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide. Endocrinology. 1990;127(1):272–7. https://doi.org/10.1210/endo-127-1-272; Epub 1990/07/01.
Thakur ML, Zhang K, Berger A, Cavanaugh B, Kim S, Channappa C, Frangos AJ, Wickstrom E, Intenzo CM. VPAC1 receptors for imaging breast cancer: a feasibility study. J Nucl Med. 2013;54(7):1019–25. https://doi.org/10.2967/jnumed.112.114876; PubMed PMID: 23651947; PMCID: PMC5506835.
67Cu-SARTATE™ peptide receptor radionuclide therapy administered to pediatric patients with high-risk neuroblastoma. Clarity Pharmaceuticals Ltd. https://clinicaltrials.gov/ct2/show/NCT04023331.
Gespach C, Bawab W, de Cremoux P, Calvo F. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells. Cancer Res. 1988;48(18):5079–83. Epub 1988/09/15
Moody TW, et al. VIP: a VIP agonist for localizing breast cancer tumors. Peptides. 1998;19:585–92.
Acknowledgments
The author thanks Dr. Prof. Richard Baum and his colleagues for their pioneer role and leadership in the establishment the modern theranostic field in general and the PCa theranostic in particular. This book will serve as a compendium of the lifelong scholarly activities and collaborative research of Dr. Prof. Richard Baum in advancing medical science and treatment of oncologic diseases. We salute him and thank him for his decades of friendship.
The author also gratefully acknowledges the contributions of his colleagues in basic, preclinical, and translational clinical investigations in exploring the role of VPAC receptors in oncologic applications and the financial support of NIH (NCI), DOD and Thomas Jefferson University.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Copyright information
© 2024 The Author(s)
About this chapter
Cite this chapter
Thakur, M.L. (2024). Can VPAC-Targeted Cu-67-TP3805 Play a Theranostic Role for Prostate Cancer?: A Quest. In: Prasad, V. (eds) Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum. Springer, Cham. https://doi.org/10.1007/978-3-031-33533-4_32
Download citation
DOI: https://doi.org/10.1007/978-3-031-33533-4_32
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-33532-7
Online ISBN: 978-3-031-33533-4
eBook Packages: MedicineMedicine (R0)